Lamotrigine 25 mg is a starter dose of an anticonvulsant medication used to treat epilepsy and prevent mood episodes in bipolar I disorder. The 25 mg tablet isn’t typically the long-term dose. Instead, it’s where most people begin treatment, with the dose gradually increasing over several weeks to reduce the risk of a serious skin reaction.
Epilepsy and Seizure Types
Lamotrigine is approved to treat several types of seizures in patients aged 2 and older. These include partial-onset seizures (which start in one area of the brain), primary generalized tonic-clonic seizures (the type involving full-body convulsions), and the generalized seizures seen in Lennox-Gastaut syndrome, a severe form of childhood epilepsy. It can be used alongside other seizure medications or, for adults 16 and older with partial-onset seizures, as a standalone treatment.
Bipolar I Disorder
Lamotrigine is also approved for maintenance treatment of bipolar I disorder, meaning it’s used to delay or prevent future mood episodes after an acute episode has already been treated. It helps reduce the return of both depressive and manic symptoms. A Cochrane review of clinical trials found that lamotrigine reduced recurrence of manic symptoms by about 33% compared to placebo and also suppressed depressive symptoms.
One important distinction: lamotrigine is not used to treat an active manic or depressive episode. Its role is prevention, keeping mood stable over time. When compared to lithium, another common mood stabilizer, lamotrigine showed similar overall effectiveness, though lithium was better at preventing manic episodes specifically.
Why the Dose Starts So Low
The 25 mg dose exists for safety reasons. Lamotrigine carries a risk of serious, potentially life-threatening skin rashes, including Stevens-Johnson syndrome, a condition where the skin blisters and peels. In clinical trials, serious rashes occurred in roughly 3 out of every 1,000 adults taking lamotrigine for epilepsy and about 1 in 1,000 adults taking it for mood disorders. The risk is higher in children under 16, at about 8 per 1,000.
Starting low and increasing slowly appears to reduce this risk. Exceeding the recommended starting dose or ramping up too quickly are both suspected of raising the chance of a serious skin reaction. This is why your prescriber will follow a strict schedule rather than jumping straight to the target dose.
The Typical Dose Increase Schedule
How quickly your dose increases depends on what other medications you’re taking. If you’re not on valproate (a common seizure and mood medication) or certain other anticonvulsants, the standard schedule looks like this:
- Weeks 1 and 2: 25 mg once daily
- Weeks 3 and 4: 50 mg once daily
- Week 5 onward: Increases of 50 mg every one to two weeks until reaching the target dose
If you are taking valproate, the ramp-up is even slower because valproate slows the body’s ability to break down lamotrigine, effectively making each dose stronger. In that case, you may start at 25 mg every other day for the first two weeks, then move to 25 mg daily, with smaller increases after that. The final maintenance dose varies widely depending on the condition being treated and what other medications are involved, but it typically ranges from 100 mg to 400 mg per day.
How Lamotrigine Works
Lamotrigine stabilizes overactive nerve cells by blocking sodium channels, which are tiny gateways that allow electrical signals to fire in the brain. Research published in the Proceedings of the National Academy of Sciences showed that two lamotrigine molecules bind to different pockets within these channels, tightening the channel’s “gate” so it stays closed. This prevents neurons from firing too rapidly, which is what happens during a seizure. The same calming effect on nerve signaling is thought to explain why it helps stabilize mood in bipolar disorder.
Common Side Effects
The most frequently reported side effects are dizziness, headache, double or blurred vision, drowsiness, nausea, and difficulty with coordination or balance. Some people also experience difficulty concentrating, dry mouth, or stomach discomfort. These effects are often most noticeable during the dose increase phase and may settle once you reach a stable dose.
Any rash that develops while taking lamotrigine should be taken seriously, even though most rashes turn out to be harmless. Because there’s no reliable way to tell early on whether a rash will become dangerous, the standard guidance is to stop the medication at the first sign of a rash unless it’s clearly unrelated to the drug. Fever, swollen glands, or flu-like symptoms alongside a rash are particular red flags. People of certain Asian backgrounds, including Han Chinese and Thai descent, may have a higher genetic risk for severe skin reactions and should let their prescriber know.
Important Drug Interactions
Lamotrigine’s levels in the body can shift significantly depending on what else you’re taking. Valproate inhibits the enzyme that breaks down lamotrigine, roughly doubling its concentration, which is why the starting dose and schedule are adjusted when the two are combined.
Estrogen-containing birth control pills have the opposite effect. In women taking lamotrigine alone, oral contraceptives can increase the rate at which lamotrigine is cleared from the body by about 60%, potentially making it less effective. This means your dose may need to go up when you start the pill and back down during the placebo week or if you stop. Interestingly, this interaction is largely neutralized in women also taking valproate, since valproate’s slowing effect on lamotrigine metabolism counteracts the speed-up from estrogen.
Pregnancy produces a similar shift. Women on lamotrigine alone saw their drug levels drop by roughly 295% from baseline to mid-pregnancy, while those also taking valproate experienced only a modest 60% change. If you’re planning a pregnancy or using hormonal contraception, your prescriber will likely want to monitor your response more closely and adjust the dose accordingly.
Off-Label Uses
Doctors sometimes prescribe lamotrigine for conditions beyond its official approvals. One example is migraine-associated vertigo. A retrospective study in Neurology found that among 33 patients who had tried both lamotrigine and topiramate (a more commonly used migraine drug), 76% reported improvement in vertigo with lamotrigine, and most of those also saw their migraines improve. Doses in that study ranged from 100 mg to 300 mg. While this evidence is preliminary, it reflects the broader pattern of lamotrigine being explored for various neurological conditions where calming overactive nerve signaling could help.